SYRS: Syros Pharmaceuticals, Inc.
About
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Key Details
Market Cap
$6.98M
P/E Ratio
-0.09
1Y Stock Return
-90.37%
1Y Revenue Growth
-95.61%
Dividend Yield
0.00%
Price to Book
-0.6
Strategies that include SYRS
Stock's related to SYRS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SIBN | 33.17% | $515.42M | -31.46% | 0.00% |
| PSQH | 31.17% | $76.13M | -59.59% | 0.00% |
| PGNY | 27.23% | $1.27B | -55.67% | 0.00% |
| LDOS | 25.77% | $21.98B | +54.90% | 0.91% |
| KALV | 25.49% | $454.27M | +23.02% | 0.00% |
| CHMI | 25.48% | $80.33M | -34.70% | 23.72% |
| PHR | 25.10% | $1.10B | +21.72% | 0.00% |
| BAX | 24.76% | $16.84B | -8.03% | 3.51% |
| VRDN | 24.69% | $1.55B | +25.13% | 0.00% |
| RCKT | 24.58% | $1.17B | -41.62% | 0.00% |
| NVRO | 24.54% | $163.38M | -73.27% | 0.00% |
| OMER | 24.33% | $447.95M | +329.44% | 0.00% |
| TVTX | 24.16% | $1.59B | +219.23% | 0.00% |
| RPTX | 24.08% | $126.26M | -39.14% | 0.00% |
| ALT | 23.17% | $597.80M | +228.32% | 0.00% |
| TME | 22.91% | $8.06B | +36.01% | 1.21% |
| ACET | 22.69% | $75.31M | -20.52% | 0.00% |
| NRIX | 22.57% | $1.58B | +259.65% | 0.00% |
| LFWD | 22.39% | $16.38M | -64.57% | 0.00% |
| GILT | 22.28% | $296.77M | -16.85% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CAR | -<0.01% | $3.57B | -42.55% | 0.00% |
| CSR | -<0.01% | $1.21B | +34.89% | 4.07% |
| BBVA | 0.01% | $55.74B | +6.84% | 7.77% |
| CCO | 0.01% | $777.63M | +18.66% | 0.00% |
| VUZI | -0.02% | $95.70M | -40.37% | 0.00% |
| MG | 0.02% | $283.75M | +37.80% | 0.00% |
| LNW | 0.03% | $8.34B | +8.03% | 0.00% |
| ABT | 0.03% | $203.38B | +14.18% | 1.87% |
| PUMP | -0.03% | $846.08M | -10.46% | 0.00% |
| ATI | 0.04% | $8.30B | +33.03% | 0.00% |
| BK | -0.04% | $57.35B | +67.05% | 2.25% |
| FICO | 0.04% | $56.92B | +119.48% | 0.00% |
| OXBR | 0.04% | $19.24M | +183.49% | 0.00% |
| BKE | -0.05% | $2.42B | +33.07% | 2.93% |
| SPRU | -0.05% | $43.34M | -31.87% | 0.00% |
| CVNA | -0.05% | $31.92B | +692.28% | 0.00% |
| KIM | 0.05% | $17.06B | +35.58% | 3.79% |
| BBW | 0.05% | $496.10M | +39.60% | 1.63% |
| AVPT | -0.05% | $3.43B | +120.22% | 0.00% |
| HTBK | 0.06% | $656.56M | +24.68% | 4.84% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -49.93% | $22.32M | +230.27% | 0.00% |
| SBUX | -26.29% | $113.39B | -3.27% | 2.32% |
| CAE | -22.26% | $7.43B | +11.42% | 0.00% |
| SU | -21.45% | $52.24B | +25.02% | 3.90% |
| DAVE | -18.96% | $1.05B | +1,371.79% | 0.00% |
| LPG | -18.63% | $1.08B | -33.27% | 0.00% |
| HNST | -15.93% | $772.35M | +306.91% | 0.00% |
| ARLP | -15.49% | $3.57B | +27.36% | 9.97% |
| CAH | -15.39% | $29.87B | +16.57% | 1.63% |
| SLF | -15.38% | $35.34B | +20.31% | 3.82% |
| DK | -15.05% | $1.16B | -32.74% | 5.48% |
| AIZ | -14.74% | $11.55B | +37.38% | 1.28% |
| GFF | -14.60% | $3.89B | +75.44% | 0.73% |
| DSP | -14.06% | $305.23M | +226.80% | 0.00% |
| BTCT | -13.85% | $58.86M | +395.83% | 0.00% |
| CQP | -13.27% | $26.11B | -7.01% | 5.93% |
| MPC | -13.12% | $51.19B | +6.76% | 2.13% |
| NTRA | -13.06% | $22.36B | +209.90% | 0.00% |
| FF | -12.94% | $224.94M | +20.56% | 4.67% |
| ACGL | -12.75% | $37.09B | +20.63% | 0.00% |
ETF's related to SYRS
News
Yahoo
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Yahoo
H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed, higher-risk myelodysplastic syndrome patients with RARA gene overexpression, did not achieve its primary endpoint. The firm removed tamibarotene from its valuation and downgraded the shares. Published first on TheFly – the ultimate source for
Yahoo
The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.
Finnhub
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression - SELECT-MDS-1 Did Not Meet its...
Yahoo
CAMBRIDGE, Mass., November 12, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Sy
Yahoo
Syros Pharmaceuticals ( NASDAQ:SYRS ) Third Quarter 2024 Results Key Financial Results Net loss: US$6.40m (loss...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.